[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

China Human Vaccine Industry Analysed in Comprehensive Huidian Research Study Now Available at MarketPublishers.com

05 Feb 2015 • by Natalie Aster

LONDON – China boasts one of the world’s largest vaccine manufacturing industries, with over 40 licensed vaccine manufacturers. As of 2013, the lot release quantity of vaccines reached 755 million doses, up 0.53% YoY. Vaccine producers mainly comprise state-run enterprises, privately-operated enterprises and foreign-funded firms in the country. The government-owned companies still dominate the vaccine market, together capturing 62% market share, with private and foreign-funded enterprises following in with market shares of around 33.8% and just over 4.2%, respectively.

Moving forward, the national vaccine market is forecast to maintain its annual average growth rate of 16%-18%, driven by a number of factors like the implementation of the National Vaccine Immunisation Plan, growing receptivity to vaccination by the public, surging trend of initiative vaccination, etc. By 2018, the value of the vaccine market is projected to hit around USD 6.47 billion.

Beijing Tiantan Biological Products, Liaoning Chengda (LCD), ChongQing ZhiFei Biological Products, Walvax Biotechnology, among others, are the most outstanding players in the domestic human vaccine field.

Comprehensive market report “Research and Investment Prospect of Human Vaccine Industry in China, 2014-2018” drawn up by Huidian Research provides a granular analysis of the Chinese human vaccine industry. The research publication thoroughly examines the marketplace, reviews the competitive dynamics and provides human vaccine market segmentation. It analyses the industry chain, export/import situation, as well as offers a discussion of the 7 leading domestic manufacturers of human vaccines including an assessment of their business performance. Insights into the investment opportunities and risks, market entry barriers, as well as the development path of the Chinese human vaccine industry are given in the report as well.

Report Details:

Research and Investment Prospect of Human Vaccine Industry in China, 2014-2018
Published: December, 2014
Pages: 56
Price: US$ 2,000.00

Other Chinese Industry Research Reports by Huidian Research Encompass:

More comprehensive market research reports by the publisher can be found at Huidian Research page.


The Market Publishers, Ltd.
Natalie Aster
Tel: +44 208 144 6009
Fax: +44 207 900 3970
[email protected] 

Analytics & News

Weekly Digest